Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$133.70
-0.3%
$133.20
$99.71
$141.23
$232.61B0.736.16 million shs3.11 million shs
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
$0.28
-4.8%
$0.29
$0.16
$2.99
$7.86M2.524.13 million shs667,856 shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$543.74
+0.6%
$536.53
$413.82
$616.00
$194.89B1.641.67 million shs704,815 shs
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
$2.41
-0.6%
$5.07
$2.23
$414.99
$5.75M1.16786,340 shs76,819 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-0.29%-0.03%-0.03%+7.42%+30.69%
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
-4.83%-23.31%-2.34%-59.61%-87.28%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
+0.58%+1.79%-1.47%+20.41%+25.05%
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
-0.62%+1.05%-64.37%-79.09%-99.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.8981 of 5 stars
2.43.04.24.52.92.52.5
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
1.9016 of 5 stars
3.05.00.00.00.90.80.0
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
4.3301 of 5 stars
2.43.00.04.03.02.51.9
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
0.1529 of 5 stars
0.02.00.00.02.40.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.76
Moderate Buy$142.616.67% Upside
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
2.00
Hold$6.002,073.91% Upside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.70
Moderate Buy$588.958.32% Upside
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest RSLS, BIAF, ABT, and ISRG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$143.00
6/9/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Sell$515.00 ➝ $440.00
6/5/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
5/22/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$590.00 ➝ $650.00
4/24/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$684.00 ➝ $635.00
4/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$630.00 ➝ $605.00
4/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$670.00 ➝ $575.00
4/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$605.00 ➝ $590.00
4/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$510.00 ➝ $470.00
4/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$600.00 ➝ $575.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$42.34B5.49$6.56 per share20.37$27.62 per share4.84
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
$8.81M0.89N/AN/A$0.17 per share1.62
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$8.35B23.33$8.04 per share67.67$46.41 per share11.72
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
$8.01M0.72N/AN/A($8.66) per share-0.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7117.3423.332.5531.89%19.01%10.82%7/17/2025 (Estimated)
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
-$9.04M-$0.72N/AN/A-110.53%-367.64%-154.15%8/13/2025 (Estimated)
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$6.8279.7371.265.7328.41%14.43%12.81%7/17/2025 (Estimated)
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
-$7.13M-$193.23N/AN/A-48.26%-251.90%-59.49%8/12/2025 (Estimated)

Latest RSLS, BIAF, ABT, and ISRG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.25N/AN/AN/A$11.01 billionN/A
7/17/2025Q2 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.92N/AN/AN/A$2.35 billionN/A
5/20/2025Q1 2025
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
N/A$18.98N/A$18.98N/A$1.11 million
5/15/2025Q1 2025
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
-$0.16-$0.16N/A-$0.16$2.11 million$1.85 million
4/22/2025Q1 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.71$1.81+$0.10$1.92$2.19 billion$2.25 billion
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
4/4/2025Q4 2024
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
-$101.50-$47.25+$54.25-$1.89$3.17 million$1.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.77%N/A30.61%54 Years
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
N/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
N/AN/AN/AN/AN/A

Latest RSLS, BIAF, ABT, and ISRG Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.26
1.78
1.27
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
0.27
0.55
0.53
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
4.98
3.97
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
N/A
1.53
0.91

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
1.64%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
22.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
1028.46 million23.64 millionNot Optionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
15,638358.42 million355.91 millionOptionable
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
502.39 million2.39 millionNot Optionable

Recent News About These Companies

ReShape Lifesciences Loans $200K to Vyome Therapeutics

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$133.70 -0.42 (-0.31%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$133.70 +0.00 (+0.00%)
As of 07/3/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

bioAffinity Technologies stock logo

bioAffinity Technologies NASDAQ:BIAF

$0.28 -0.01 (-4.83%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$0.28 +0.00 (+0.36%)
As of 07/3/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$543.74 +3.14 (+0.58%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$543.08 -0.66 (-0.12%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

ReShape Lifesciences stock logo

ReShape Lifesciences NASDAQ:RSLS

$2.40 -0.02 (-0.62%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$2.41 +0.00 (+0.04%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.